June 19, 2020 / 5:29 AM / 17 days ago

BRIEF-Roche Holding AG - Impassion031 Study Is The Second Positive Phase Iii Study From Roche Demonstrating The Benefit Of Tecentriq In Tnbc

Roche Holding AG:

* ROCHE HOLDING AG - TECENTRIQ IN COMBINATION WITH CHEMOTHERAPY MEETS PRIMARY ENDPOINT OF IMPROVED PATHOLOGICAL COMPLETE RESPONSE AS INITIAL TREATMENT FOR PEOPLE WITH EARLY TRIPLE-NEGATIVE BREAST CANCER

* ROCHE HOLDING AG - MET ITS PRIMARY ENDPOINT BY DEMONSTRATING A STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT IN PATHOLOGICAL COMPLETE RESPONSE

* ROCHE HOLDING AG - FEWER PATIENTS WHO RECEIVED TECENTRIQ COMBINATION AS NEOADJUVANT TREATMENT HAD EVIDENCE OF TUMOUR TISSUE DETECTABLE AT THE TIME OF SURGERY IN COMPARISON TO THE CONTROL ARM

* ROCHE HOLDING AG - IMPASSION031 STUDY IS THE SECOND POSITIVE PHASE III STUDY FROM ROCHE DEMONSTRATING THE BENEFIT OF TECENTRIQ IN TNBC Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below